NiKem Research s.r.l. And GlaxoSmithKline (GSK) Enter Into A Research Partnership Agreement

Today NiKem Research announced that it has signed a research and development agreement with GSK for the discovery of Opioid Receptor Like-1 (ORL-1) modulators. Under the terms of the agreement, GSK will licence their ORL-1 technology to NiKem. NiKem will perform the chemical identification, optimization and preclinical pharmacological profiling of novel ORL-1 receptor agonists and antagonists in a broad range of potential CNS-related therapeutic indications.